Anika Therapeutics ANIK Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $41.02M-28.6% | $57.48M-0.9% | $57.99M+9.1% | $53.17M-0.4% | $53.37M-4.1% | ||
| $25.77M+8.8% | $23.69M+6.8% | $22.19M-7.4% | $23.96M+9.0% | $21.99M-6.8% | ||
| —— | —— | —— | —— | —— | ||
| $22.84M+21.6% | $18.79M+15.4% | $16.28M-3.8% | $16.92M-20.7% | $21.34M-10.4% | ||
| $3.94M+15.7% | $3.4M-33.7% | $5.13M-2.7% | $5.27M-9.3% | $5.82M+5.8% | ||
| $93.56M-9.5% | $103.36M+1.7% | $101.59M+2.3% | $99.32M-3.1% | $102.51M-9.8% | ||
| $39.72M-1.5% | $40.32M-0.9% | $40.68M0.0% | $40.68M+0.6% | $40.46M+3.8% | ||
| $25.43M-2.0% | $25.94M+7.1% | $24.23M-2.0% | $24.72M-1.8% | $25.18M-2.0% | ||
| $7.89M-2.0% | $8.05M0.0% | $8.05M-0.1% | $8.06M+8.5% | $7.42M+4.2% | ||
| $1.65M0.0% | $1.65M0.0% | $1.65M-0.7% | $1.66M-27.2% | $2.28M-8.4% | ||
| $1.15M-9.8% | $1.28M+1.9% | $1.25M-0.2% | $1.25M+5.6% | $1.19M+0.9% | ||
| $4.3M+6.7% | $4.03M-26.7% | $5.51M-0.8% | $5.55M-3.1% | $5.73M+1.2% | ||
| $179.39M-5.7% | $190.27M+0.4% | $189.44M+0.9% | $187.68M-1.5% | $190.61M-6.0% | ||
| $6.34M+4.9% | $6.04M+27.7% | $4.73M-0.8% | $4.77M-9.6% | $5.28M-6.1% | ||
| $14.63M-7.8% | $15.87M+10.5% | $14.36M+26.9% | $11.31M-10.4% | $12.62M-7.0% | ||
| $1.94M-5.4% | $2.05M+19.0% | $1.73M-5.0% | $1.82M-3.1% | $1.87M-2.3% | ||
| —— | —— | -$372K-142% | $888K+58.0% | $562K-15.5% | ||
| $20.97M-4.3% | $21.91M+14.8% | $19.09M+18.7% | $16.08M-10.2% | $17.9M-23.2% | ||
| $23.79M-1.7% | $24.2M+6.2% | $22.78M-1.7% | $23.17M-1.7% | $23.56M-1.9% | ||
| $726K+3.6% | $701K-7.9% | $761K+0.7% | $756K+1.6% | $744K-3.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $133K-4.3% | $139K-3.5% | $144K0.0% | $144K+0.7% | $143K-0.7% | ||
| $83.35M-4.7% | $87.5M-4.0% | $91.11M+1.8% | $89.46M+2.2% | $87.56M-1.6% | ||
| $55.73M-8.3% | $60.79M+0.5% | $60.5M-3.7% | $62.82M-5.9% | $66.79M-6.8% | ||
| -$5.31M-7.1% | -$4.96M-0.4% | -$4.94M-3.9% | -$4.76M+22.1% | -$6.1M+10.0% | ||
| $133.9M-6.7% | $143.47M-2.3% | $146.81M-0.6% | $147.67M-0.5% | $148.4M-3.6% | ||
| $179.39M-5.7% | $190.27M+0.4% | $189.44M+0.9% | $187.68M-1.5% | $190.61M-6.0% | ||
| $25.77M+8.8% | $23.69M+6.8% | $22.19M-7.4% | $23.96M+9.0% | $21.99M-6.8% | ||
| $4.3M+6.7% | $4.03M-26.7% | $5.51M-0.8% | $5.55M-3.1% | $5.73M+1.2% | ||
| $25.43M-2.0% | $25.94M+7.1% | $24.23M-2.0% | $24.72M-1.8% | $25.18M-2.0% | ||
| $1.15M-9.8% | $1.28M+1.9% | $1.25M-0.2% | $1.25M+5.6% | $1.19M+0.9% | ||
| $1.65M0.0% | $1.65M0.0% | $1.65M-0.7% | $1.66M-27.2% | $2.28M-8.4% | ||
| $25.43M-2.0% | $25.94M+7.1% | $24.23M-2.0% | $24.72M-1.8% | $25.18M-2.0% | ||
| $4.3M+6.7% | $4.03M-26.7% | $5.51M-0.8% | $5.55M-3.1% | $5.73M+1.2% | ||
| $25.43M-2.0% | $25.94M+7.1% | $24.23M-2.0% | $24.72M-1.8% | $25.18M-2.0% | ||
| $4.3M+6.7% | $4.03M-26.7% | $5.51M-0.8% | $5.55M-3.1% | $5.73M+1.2% | ||
| $14.63M-7.8% | $15.87M+10.5% | $14.36M+26.9% | $11.31M-10.4% | $12.62M-7.0% | ||
| $25.74M-2.0% | $26.25M+7.1% | $24.51M-1.9% | $24.99M-1.8% | $25.44M-1.9% | ||
| $83.35M-4.7% | $87.5M-4.0% | $91.11M+1.8% | $89.46M+2.2% | $87.56M-1.6% | ||
| $133K-4.3% | $139K-3.5% | $144K0.0% | $144K+0.7% | $143K-0.7% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $5.68M+0.8% | $5.64M-13.0% | $6.48M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Anika Therapeutics's total assets?
- Anika Therapeutics (ANIK) holds $179.4M in total assets, down 5.9% year over year.
- How much debt does Anika Therapeutics have?
- Anika Therapeutics carries $25.7M in total debt against $133.9M of shareholders' equity, a debt-to-equity ratio of 0.19.
- How much cash does Anika Therapeutics have?
- Anika Therapeutics holds $41.0M in cash and equivalents.
- Can Anika Therapeutics cover its short-term obligations?
- Its current ratio is 4.46 — current assets exceed current liabilities.
- Where does Anika Therapeutics's balance sheet data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
